TOKYO-METROPOLITAN
6.7.2021 16:06:06 CEST | Business Wire | Press release
With the Olympic Games just around the corner, Tokyo Governor Koike Yuriko sent a video message to the world's media inviting them to the Tokyo Media Center (TMC) provided by the Tokyo Metropolitan Government. TMC offers services not only for members of the press coming to Tokyo but also those working from their home countries, a great opportunity to cover the Games and the City online no matter how far away. Registration is required for full use of member services. Do not miss the opportunity to receive regular full online updates about what’s happening in Tokyo during the Games!
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210706005509/en/
Find the video invitation form Koike Yuriko, the Governor of Tokyo at https://tokyo.mediacenter.jp/about/
Register Now!
| 1) | Access TMC’s registration page at https://tokyo.mediacenter.jp/?modal=register |
|
| 2) | Submit your name and email for Account Registration. |
|
| 3) | Register your ID and proof of employment with the Accreditation Application at https://tokyo.mediacenter.jp/login/ |
Benefits of TMC Online Service
1) |
TMC Web will be your home for various information during the Games, including photos, videos, data regarding Tokyo and more. |
|
2) |
TMC Newsletters will update you twice a day with what’s happening in Tokyo during the Games. |
|
3) |
TMC Briefings will live-stream daily briefings from the Tokyo Metropolitan Government. You can cast questions to the officials. They are scheduled from 12:30 pm to 1:00 pm, Japan Standard Time (JST), from July 23 to August 8 and from August 24 to September 5, 2021. |
|
4) |
TMC Talks will video-stream daily live presentations and recorded messages by Governor Koike and/or global leaders from various fields such as sports, culture and urban development. The main theme will be the future of Tokyo. You can cast questions to speakers via online tools. More details about TMC Talks will be announced soon. They are scheduled from 2:00 pm to 2:40 pm, JST, from July 21 to August 8 and from August 23 to September 5, 2021. |
|
5) |
TMC Online Concierge will answer your questions and provide consultations about Tokyo-related coverage and photography. It will be available between 8:00 am and 10:00 pm, JST, from July 21 to August 8 and from August 23 to September 5, 2021. |
We are looking forward to serving you soon!
About the Tokyo Media Center (TMC)
The Tokyo Media Center (TMC) has been set up by the Tokyo Metropolitan Government to serve as a media coverage base for domestic and international media during the Olympic and Paralympic Games Tokyo 2020. TMC provides information related to the host city Tokyo as well as the Tokyo 2020 Games. It is totally separate from the Main Press Centre (MPC) and International Broadcast Centre (IBC), which are operated by the Tokyo 2020 Organising Committee.
Website
URL: https://tokyo.mediacenter.jp/
Facilities
Date and Time of Opening: |
|
Wednesday, July 21, 2021 to Monday, August 9, 8:00 am to 10:00 pm, JST |
|
Monday, August 23, 2021 to Sunday, September 5, 8:00 am to 10:00 pm, JST |
|
* A pre-opening is scheduled on Monday, July 19 and Tuesday, July 20. The details will be announced separately. |
|
Access: |
Tokyo Sports Square, 2nd and 3rd Floor (address: Marunouchi 3-8-3, Chiyoda-ku, Tokyo) |
1 minute walk from JR Yurakucho Station and Tokyo Metro Yurakucho Station |
|
Services: |
Workspace and lounge |
Approximately 120 seats available to create a work environment for journalists. |
|
A drink corner offering refreshments will also be provided. |
|
Information Desk |
|
Staff will respond to inquiries regarding facilities usage. Upon first entrance, guests will receive a media kit which includes complimentary Tokyo-related giveaways. |
|
Japan Showcase |
|
The Japan National Tourism Organization (JNTO) will have booths to promote Japan’s various regions and traditional culture. |
|
Japanese Liquors Booth |
|
The National Tax Agency (NTA) will have a booth to introduce Japanese liquors. |
|
Internet Connection |
|
Wi-fi available for use by registered members. |
|
* Detailed information such as COVID-19 countermeasures and how to enter the facilities will be periodically updated on the TMC website and TMC Briefings. |
|
TOKYO UPDATES
Tokyo Metropolitan Government (TMG) launched a new media platform to show the world the ever-changing face of Tokyo now and the future in May 2021. This platform features content such as articles which focus on the attractions of Tokyo and the people who live, study, and work in the city. Please be sure to check it out.
URL: https://www.tokyoupdates.metro.tokyo.lg.jp/en/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210706005509/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom